Related Experiment Video

Updated: Nov 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia

Dominique S Genest1, Karyne Pelletier1, Gabriel Dallaire2

  • 1Division of Nephrology, Hôpital du Sacré-Cœur de Montréal, Quebec, Canada.

Kidney International Reports
|March 18, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.5K

Related Experiment Videos

Last Updated: Nov 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Value of Kidney Immunodeposits and Urinary Complement Activation Fragments in IgAN.

Kidney international reports·2026

Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis.

BMJ (Clinical research ed.)·2026

Immune Deposits, Complement Activation, and APOL1 Risk Variants in Focal Segmental Glomerulosclerosis.

American journal of nephrology·2026

Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines.

Canadian journal of kidney health and disease·2026

A Multinational Cohort Study of Dialysis Initiation During Pregnancy.

Kidney international reports·2025

The risk of sodium overcorrections in severe hyponatremia and the utility of desmopressin: a large retrospective study.

Clinical kidney journal·2025

An International Expert Consensus Statement and Guidance Document on Implementation of Nutritional Supplementation in Patients on Dialysis.

Kidney international reports·2026

Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis.

Kidney international reports·2026

Dementia in Advanced Kidney Disease by Race and Ethnicity and Neighborhood Factors.

Kidney international reports·2026

Corrigendum to "Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy" [Kidney International Reports Volume 11, Issue 8, August 2026, 106643].

Kidney international reports·2026

Kidney Allograft Outcomes in Borderline and T Cell-Mediated Rejection With Microvascular Inflammation.

Kidney international reports·2026

Diffusion MRI Radiomics Predict Renal Function Decline in ADPKD.

Kidney international reports·2026

[Sarcoidosis from an immunological perspective - experience-based diagnosis and treatment with targeted therapies].

Therapeutische Umschau. Revue therapeutique·2026

[Immune-related adverse events of immune checkpoint inhibitors].

Therapeutische Umschau. Revue therapeutique·2026

Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data.

Folia medica·2026

Correction: A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Frontiers in immunology·2026

Expanded dendritic cells loaded with placental gp96 to generate antigen-specific T cells for anti-tumor immunity: an in vitro study.

Central-European journal of immunology·2026

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets.

MedComm·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us